Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial.

@article{Xie2013PersonalizedAT,
  title={Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial.},
  author={Xiang Xie and Y. Ma and Yining Yang and Xiao-Mei Li and Y. Zheng and Xiang Ma and Z. Fu and Ba Bayinsilema and Y. Li and Zi-xiang Yu and You Chen and Bang-dang Chen and F. Liu and Ying Huang and C. Liu and Gulinaer Baituola},
  journal={International journal of cardiology},
  year={2013},
  volume={168 4},
  pages={
          3736-40
        }
}
OBJECTIVE The objective of this study is to compare personalized antiplatelet therapy according to CYP2C19 phenotype with conventional antiplatelet therapy in patients after percutaneous coronary intervention (PCI). METHODS A total of 600 patients with coronary artery disease (CAD) undergoing PCI randomly received a personalized antiplatelet therapy (group A; n=301) or conventional antiplatelet treatment (group B; n=299). For group A, antiplatelet therapy was performed according to CYP2C19… Expand
Personalized Antiplatelet Therapy Based on CYP2C19 Genotypes in Chinese ACS Patients Undergoing PCI: A Randomized Controlled Trial
TLDR
Personalized antiplatelet therapy that is based on CYP2C19 genotypes could decrease MACCE within a 12-month period in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention. Expand
The effect of CYP2C19 genotype-guided antiplatelet therapy on outcomes of selective percutaneous coronary intervention patients: an observational study.
Aim: To observe if personalized antiplatelet therapy according to the CYP2C19 phenotype can improve the outcomes of patients receiving selective percutaneous coronary intervention (PCI). Methods: InExpand
Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing PCI: a randomized controlled clinical trial.
TLDR
It is suggested that personalized antiplatelet therapy according to MAR can significantly improve the net clinical benefit 180 days after PCI, and theNet clinical adverse events were significantly reduced in the personalized group at 30 Days after PCI compared to the standard group. Expand
The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials
TLDR
In patients with ACS or undergoing PCI, CYP2C19 genotype-guided antiplatelets therapy displayed benefit over conventional antiplatelet therapy in reducing the risk of MACE and myocardial infarction, without increasing bleeding risk. Expand
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
TLDR
These data from real-world observations demonstrate a higher risk for cardiovascular events in patients with a CYP2C19 loss-of-function allele if clopidogrel versus alternative therapy is prescribed. Expand
Genotype-guided antiplatelet therapy compared with standard therapy for patients with acute coronary syndromes or undergoing percutaneous coronary intervention: A systematic review and meta-analysis.
TLDR
Genotype-guided antiplatelet treatment could reduce the risk of HTPR, MI and ST compared with standard therapy in patients with ACS or undergoing PCI, and no significant difference was found between two groups in the major bleeding events. Expand
Genotype-guided antiplatelet therapy compared with conventional therapy for patients with acute coronary syndromes: a systematic review and meta-analysis
TLDR
Genotype-guided strategies could reduce the rates of cardiovascular events without increasing bleeding events compared with conventional treatment in ACS and future multi-centre genotype-based randomized control trials are required to confirm these findings. Expand
Genotype-guided personalization of antiplatelet treatment: A meta-analysis of patients with ACS or undergoing PCI.
TLDR
Genotype-guided antiplatelet treatment with P2Y12 inhibitors could decrease the risks of HTPR, all-cause mortality, MI and ST in patients with ACS or undergoing PCI. Expand
Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention
TLDR
Emerging results from registry studies and small clinical trials of CYP2C19 genotype-guided antiplatelet therapy following percutaneous coronary intervention offer new insight and contribute to a growing evidence base that supports the clinical utility of a genotyping strategy to personalize antiplatelets therapy selection. Expand
Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y12 Inhibitor Selection and Clinical Outcomes in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention: A Real-World Study in China
  • Yi Zhang, Xiujin Shi, +12 authors Yang Lin
  • Medicine
  • Frontiers in Pharmacology
  • 2020
TLDR
This study confirms that efficiently returned CYP2C19 genotype results did partially guide cardiologists to prescribe ticagrelor for patients with a LOF allele, and that clopidogrel had a higher risk of MACCE than ticgrelor in these patients, which provides support for the implementation of CYP 2C19 gene-guided antiplatelet therapy in clinical practice. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 30 REFERENCES
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
TLDR
The CYP2C19*2 genetic variant is a major determinant of prognosis in young patients who are receiving clopidogrel treatment after myocardial infarction and is the only independent predictor of cardiovascular events. Expand
Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis.
TLDR
Compared with the dual antiplatelet regimen, triple anti-platelet therapy seemed to be more effective in preventing thrombotic complications after stenting without an increased risk of side effects. Expand
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT
TLDR
TAT did not show superiority in reducing the composite of adverse cardiovascular outcomes after DES implantation, and the greater reduction of platelet reactivity by addition of cilostazol to conventional DAT was not greater. Expand
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
TLDR
CYP2C19*2 genotype was associated with diminished platelet response to clopidogrel treatment and poorer cardiovascular outcomes, and patients with the CYP2C 19*2 variant were more likely to have a cardiovascular ischemic event or death during 1 year of follow-up. Expand
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study
TLDR
In patients with acute coronary syndrome receiving aspirin, a strategy of clopidogrel pretreatment followed by long-term therapy is beneficial in reducing major cardiovascular events, compared with placebo. Expand
Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial
TLDR
Point-of-care genetic testing after PCI can be done effectively at the bedside and treatment of identified CYP2C19*2 carriers with prasugrel can reduce high on-treatment platelet reactivity. Expand
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.
TLDR
CYP2C19*2 carrier status is significantly associated with an increased risk of stent thrombosis following coronary stent placement and the risk of ST was highest in patients with the CYP2C 19 *2/*2 genotype. Expand
Validation of the Bleeding Academic Research Consortium Definition of Bleeding in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
TLDR
The present study demonstrated a close association between bleeding events defined according to BARC and 1-year mortality after PCI. Expand
High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation results of the ARMYDA-150 mg (antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized study.
TLDR
For patients undergoing percutaneous coronary intervention, the 150-mg/day clopidogrel maintenance dose is associated with stronger platelet inhibition, improvement of endothelial function, and reduction of inflammation, compared with the currently recommended 75- mg/day regimen. Expand
Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.
TLDR
Compared with high-MD clopidogrel, adjunctive cilostazol significantly enhances platelet inhibition and reduces the rate of HPR, especially in AMI patients with CYP2C19 loss-of-function variants. Expand
...
1
2
3
...